Ampligen and Imfinzi in Phase 2 Pancreatic Cancer Trial
AIM ImmunoTech has dosed the first patient in Phase 2 of its Phase 1b/2 clinical trial, DURIPANC, evaluating Ampligen...
eClinical Tech News
Alzamend Neuro Starts Phase 2 Trial of AL001 at Mass General
Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system,...
Candel Therapeutics Announces Positive CAN-2409 Trial Data
Candel Therapeutics announced positive final overall survival data from its Phase 2 trial of CAN-2409 in patients with borderline...
Regeneron db-oto Results Show Hearing Improvement in Children with Genetic Hearing Loss
Regeneron Pharmaceuticals announced updated positive data from its ongoing Phase 1/2 CHORD trial of DB-OTO, a gene therapy for...
Synergia Medical Announces Strong Results for nao.vns First-in-Human Study
Synergia Medical’s NAO.VNS™ device, implanted in five patients in Belgium, has met its primary safety endpoint in the AURORA...
Allo-Inkt Combination Data in 2L Gastric Cancer at AACR
MiNK Therapeutics presented Phase 2 data at the AACR IO Annual Meeting showcasing the potential of its allogeneic iNKT...
Leronlimab Shows Promise in mTNBC Patient Survival
CytoDyn Inc. announced encouraging survival outcomes in a group of patients with metastatic triple-negative breast cancer (mTNBC) treated with...
Leti-101 Shows Promise in Preclinical Huntington’s Disease Study
ElevateBio has unveiled preclinical data for LETI-101, a CRISPR-based therapy for Huntington’s Disease (HD) being developed by its subsidiary,...
FDA Grants Auron Therapeutics Fast Track Designation for AUTX-703 to Treat AML
Auron Therapeutics received FDA Fast Track designation for AUTX-703, an oral KAT2A/B degrader, for treating relapsed or refractory acute...
Duvakitug Shows Promise in Ulcerative Colitis and Crohn’s Disease
Teva Pharmaceuticals and Sanofi announced positive Phase 2b results for duvakitug, a novel antibody targeting TL1A, in patients with...